Montana HB774 revises laws to ensure equal access to nonopioid and opioid drugs in Medicaid and commercial insurance.
Montana HB774 generally revises laws relating to drugs, ensuring that nonopioid drugs for pain management are not disadvantaged compared to opioid drugs in Medicaid and commercial insurance. The bill mandates that nonopioid drugs approved by the FDA for pain treatment cannot be placed at a disadvantage in terms of coverage or cost-sharing compared to opioid drugs. It applies to nonopioid drugs immediately upon FDA approval. The bill also requires health maintenance organizations to make their utilization review plans accessible and to notify healthcare providers of any changes.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.